Role of paraoxonase-1 as a diagnostic marker for feline infectious peritonitis

Meazzi, Sara; Paltrinieri, Saverio; Lauzi, Stefania; Stranieri, Angelica; Brentali, I.; Ferriani, Riccardo; Rossi, G.; Giordano, Alessia

doi:10.1016/j.tvjl.2021.105661

Cited by 3 publications

(5 citation statements)

References 36 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the prevalence of coronary artery diseases such as atherosclerosis and their mortality is increasing globally (26,31). Therefore, finding compounds that can increase the activity of this enzyme will be very effective in preventing atherosclerosis (9). The result of the current study showed that the combination of felodipine and enalapril in the treatment of essential hypertension with coronary artery disease can significantly enhance PON1 gene expression in the study group in comparison with the control group.…”

Section: Comparison Of Adverse Reactionsmentioning

confidence: 59%

“…Although all paraoxonases can hydrolyze longchain aromatic and aliphatic lactones, PON-1 has arylesterase activity, too. There is ample evidence that PON-1 may have a protective effect on atherogenesis (9). PON-1 seems to be the main factor in the antiinflammatory function of HDL by preventing LDL oxidation.…”

Section: Comparison Of Adverse Reactionsmentioning

confidence: 99%

“…Paraoxonase (PON) is a glycoprotein enzyme that binds to the surface of high-density HDL lipoproteins, and its activity is highly correlated with cardiovascular disease and tissue damage in some organs. Its levels have been studied in patients with hypertension (9).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of felodipine and enalapril in the treatment of essential hypertension with coronary artery disease and the effect on levels of Salusin-β, Apelin, and PON1 gene expression in patients

Zhang

Jin

et al. 2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

This study aimed to analyze the effect of felodipine combined with enalapril in the treatment of patients with essential hypertension and coronary artery disease. Also, the effect of these medicines was evaluated on the peripheral blood Salusin-β, Apelin levels, and PON1 gene expression. For this purpose, 110 patients with essential hypertension combined with coronary heart disease, admitted to the hospital from January 2019 to January 2021, were selected and randomly divided into two groups. The control group was given felodipine treatment alone, and the study group was treated with combined application of felodipine and enalapril. The treatment effect, peripheral blood Salusin-β, Apelin, PON1 gene expression, and the safety of medication were compared between the two groups. The results showed that the post-treatment systolic blood pressure in the study group was 119.77 ± 5.23 mm Hg and diastolic blood pressure was 86.84 ± 5.42 mm Hg, both of which were significantly lower than those in the control group (127.81 ± 6.92 mm Hg and 95.13 ± 6.08 mm Hg), with statistically significant differences (p<0.05). The effective rates of the study group and the control group were 92.73% and 74.54% respectively, with statistically significant differences (P<0.05). The post-treatment peripheral blood Salusin-βlevel in the study group was 3.77±0.53mmol/L, and Apelin was 1.94±0.58μg/L, with statistically significant differences compared to the control group (P<0.05). The PON1 gene expression in the study group was higher than those in the control group after treatment (P<0.05). Also, the results showed that there was no statistical difference in adverse reactions between the two groups (P>0.05). According to these results, the combination of felodipine and enalapril in patients with essential hypertension combined with coronary artery disease can effectively lower the patients' blood pressure and improve their peripheral blood Salusin-β, Apelin levels, and PON1 gene expression, thus enhancing the patients' therapeutic effect with few adverse effects and high safety.

show abstract

Section: Comparison Of Adverse Reactionsmentioning

confidence: 59%

Section: Comparison Of Adverse Reactionsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of felodipine and enalapril in the treatment of essential hypertension with coronary artery disease and the effect on levels of Salusin-β, Apelin, and PON1 gene expression in patients

Zhang

Jin

et al. 2022

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

show abstract

“…Significantly lower PON‐1 activity was observed in cats with FIP compared with healthy cats; moreover, cats with effusive forms showed significantly lower PON‐1 and higher SAA concentrations compared with cats with noneffusive forms 109 . PON‐1 activity can accurately discriminate cats with FIP from cats without FIP, but with similar clinical presentations 110 . A threshold of 78.30 U/L yielded a sensitivity of 100% and a specificity of 50.4%, while a threshold of 24.90 U/L maximized specificity (94.4%) and had a sensitivity of 44.1%, making PON‐1 activity a good confirmatory test for FIP 110 …”

Section: Future Perspectivesmentioning

confidence: 95%

“…PON‐1 activity can accurately discriminate cats with FIP from cats without FIP, but with similar clinical presentations 110 . A threshold of 78.30 U/L yielded a sensitivity of 100% and a specificity of 50.4%, while a threshold of 24.90 U/L maximized specificity (94.4%) and had a sensitivity of 44.1%, making PON‐1 activity a good confirmatory test for FIP 110 …”

Section: Future Perspectivesmentioning

confidence: 99%

Acute phase proteins in cats: Diagnostic and prognostic role, future directions, and analytical challenges

Rossi

2023

Veterinary Clinical Pathol

View full text Add to dashboard Cite

While clinical studies on acute phase proteins (APPs) have significantly increased in the last decade, and most commercial labs are now offering major APPs in their biochemical profiles, APP testing has not been widely adopted by veterinary clinical pathologists and veterinarians. Measurement of APP concentration is a useful marker for detecting the presence or absence of inflammation in cats with various diseases. APPs can also be reliably measured in different biological fluids (eg, effusions and urine) to improve their diagnostic utility. Measurement of APPs can be extremely beneficial in cats with feline infectious peritonitis (FIP) to discriminate between FIP and non‐FIP cats with similar clinical presentations. Additional benefits come from multiple and sequential measurements of APPs, particularly in the assessment of therapeutic efficacy. APPs are more sensitive than WBC counts for early detection of inflammation and to demonstrate an early remission or recurrence of the diseases. Given the potential utility of APPs, more studies are warranted, with a particular focus on the applications of APPs to guide the length of antimicrobial therapies, as suggested by the antimicrobial stewardship policy. New inflammatory markers have been discovered in human medicine, with a higher specificity for distinguishing between septic versus nonseptic inflammatory diseases. It is desirable that these new markers be investigated in veterinary medicine, to further test the power of APPs in diagnostic setting.

show abstract

Clinical enzymology of the dog and cat

Oikonomidis,

Milne

2023

Aust Veterinary J

View full text Add to dashboard Cite

Clinical enzymology studies the enzyme activity in serum or other body fluids for the diagnosis, prognosis or monitoring of a variety of diseases. Clinical enzymology has greatly benefited from advances in technology and is now an integral part of laboratory analysis. However, to maximise the clinical benefits of serum enzyme measurement, clinicians and clinical pathologists must have a good understanding of the pathophysiology behind serum enzyme alterations. They must also be aware of the preanalytical and analytical factors that can affect the accuracy of serum enzyme activity measurement. This review article first covers the basic concepts of clinical enzymology and the general mechanisms related to serum enzyme alterations. Then, the review discusses the potential effects of various preanalytical and analytical factors on enzyme activity measurement. Lastly, it explores the pathophysiology and clinical use of various serum enzymes in canine and feline medicine. The present review article aims to be a comprehensive one‐stop source for clinical pathologists and small animal practitioners.

show abstract

Role of paraoxonase-1 as a diagnostic marker for feline infectious peritonitis

Cited by 3 publications

References 36 publications

Efficacy of felodipine and enalapril in the treatment of essential hypertension with coronary artery disease and the effect on levels of Salusin-β, Apelin, and PON1 gene expression in patients

Efficacy of felodipine and enalapril in the treatment of essential hypertension with coronary artery disease and the effect on levels of Salusin-β, Apelin, and PON1 gene expression in patients

Acute phase proteins in cats: Diagnostic and prognostic role, future directions, and analytical challenges

Clinical enzymology of the dog and cat

Contact Info

Product

Resources

About